Beta-blocker efficacy for intra- and interdialytic hypertension patients: a systematic review and meta-analysis

Hartono, Eugenia Maria Alodia and Saputra, Felicia Fransisca and Permata, Angeline Asti Shiela and Wibowo, Jeanne Gabrielle (2024) Beta-blocker efficacy for intra- and interdialytic hypertension patients: a systematic review and meta-analysis. International Urology and Nephrology, 56 (7). pp. 2279-2289. ISSN 03011623

[thumbnail of Beta-blocker efficacy for intra- and interdialytic hypertension patients.pdf] Text
Beta-blocker efficacy for intra- and interdialytic hypertension patients.pdf - Published Version
Restricted to Registered users only

Download (1MB) | Request a copy

Abstract

Purpose: Intradialytic hypertension affects 5–15 of hemodialysis patients, yet relevant studies are relatively scarce. It is also associated with higher interdialytic blood pressure. Beta-blockers can be preferred as antihypertensive drugs due to their superior blood pressure control, decreased risk of cardiovascular events, improved endothelial cell function, and decreased noradrenaline levels. Through this study, beta-blocker antihypertensive effects in intra- and interdialytic hypertension were analyzed. Methods: Systematic review and meta-analysis were performed following PRISMA guidelines. We registered our PROSPERO protocol (Registration ID: CRD42023446184) and included relevant full-text clinical trials or RCTs from 2008 to 2023 with predetermined keywords and criteria from multiple databases including PUBMED, COCHRANE, SCOPUS, and citation searching. Seven eligible articles were included in this review study. Results: Four studies with 82 participants for intradialytic hypertension evaluation were included. Meta-analysis showed a decrease in SBP in intradialytic hypertensive patients after beta-blocker intervention, with a significant estimated mean difference of − 15.19 mmHg (P < 0.00001; 95 CI − 19.47 to − 10.91). Supporting previous data, SBP remains constant between pre- and post-dialysis with beta-blocker therapy, with an insignificant estimated mean difference of − 2.72 mmHg (P = 0.29; 95 CI − 7.80 to 2.36). Whereas five studies with 142 participants were included for interdialytic hypertension evaluation. Meta-analysis shows a significant decrease in SBP before to after therapy, with an estimated mean difference of − 10.92 (P < 0.0001; 95 CI − 16.33 to − 5.51). Conclusion: Beta-blocker treatment resulted in significant reductions in post-hemodialysis systolic blood pressure among intra- and interdialytic hypertensive patients. © The Author(s), under exclusive licence to Springer Nature B.V. 2024.

Item Type: Article
Additional Information: Cited by: 1
Uncontrolled Keywords: Adrenergic beta-Antagonists; Humans; Hypertension; Renal Dialysis; Treatment Outcome; beta adrenergic receptor blocking agent; bisoprolol; carvedilol; metoprolol; nebivolol; beta adrenergic receptor blocking agent; drug efficacy; end stage renal disease; hemodialysis; human; hypertension; interdialytic hypertension; intradialytic hypertension; meta analysis; Newcastle-Ottawa scale; outcome assessment; randomized controlled trial (topic); Review; risk assessment; risk factor; systematic review; systolic blood pressure; complication; drug therapy; hemodialysis; treatment outcome
Subjects: R Medicine > RC Internal medicine > RC0321 Neuroscience. Biological psychiatry. Neuropsychiatry
Divisions: Faculty of Medicine, Public Health and Nursing > Non Surgical Divisions
Depositing User: Ani PURWANDARI
Date Deposited: 05 Aug 2025 01:42
Last Modified: 05 Aug 2025 01:42
URI: https://ir.lib.ugm.ac.id/id/eprint/19812

Actions (login required)

View Item
View Item